Importance Mixed treatment with dabrafenib and trametinib (CombiDT) achieves clinical responses in mere ~15% of BRAF inhibitor (BRAFi)-refractory metastatic melanoma patients, as opposed to the high activity seen in BRAFi-na?ve individuals. and bloodstream was examined for degrees of circulating BRAFV600. Primary outcome measures Main endpoint was general response price (ORR). Progression-free success (PFS) and general… Continue reading Importance Mixed treatment with dabrafenib and trametinib (CombiDT) achieves clinical responses